Pemphigus Foliaceus: Superficial Blisters, Diagnosis, and Treatment

Pemphigus foliaceus (PF) is an uncommon autoimmune blistering disease that mainly affects the outer layers of the skin. The blisters are so shallow and fragile that many people never see a complete blister: instead, the first clues may be sore, crusted, scaly, or raw-looking patches on the scalp, face, chest, or back. Unlike pemphigus vulgaris, PF usually does not involve the mouth or other mucous membranes.

Because early PF can resemble eczema, seborrheic dermatitis, impetigo, or a sun-sensitive rash, appearance alone is not enough to diagnose it. A dermatologist typically combines a skin examination with carefully selected biopsies and antibody testing. Treatment is individualized and may range from topical medicine for limited disease to systemic immune-directed treatment for more extensive disease.

When to arrange care: New or recurring fragile blisters, persistent crusted erosions, or unexplained skin tenderness deserve medical assessment, especially if they are spreading. Seek prompt care for fever, rapidly increasing redness or pain, pus, or feeling unwell; widespread skin loss or dehydration symptoms need urgent evaluation.

In PF, antibodies interfere with adhesion between skin cells near the epidermal surface. The resulting blister roof is delicate, so a shallow erosion or crust may be more visible than an intact blister.

What pemphigus foliaceus is

Pemphigus is a family of autoimmune disorders in which antibodies interfere with the connections that hold surface cells together. In PF, the main target is desmoglein 1, a protein in desmosomes, the structures that help neighboring keratinocytes stay attached. When cell-to-cell adhesion weakens, fluid can collect within the upper epidermis and form a superficial blister. This process is called acantholysis.

The split sits close to the skin surface. A small amount of friction can open it, which explains why the condition may appear as erosions, thin scale, or crust rather than round, fluid-filled blisters. These findings do not mean that the person is failing to keep the skin clean; they reflect the fragility of the affected skin.

PF is not caused by poor hygiene and is not contagious. It can occur in people of different backgrounds and ages, though it is often diagnosed in adulthood. Most cases are sporadic. A less common endemic form, called fogo selvagem, occurs in particular regions of South America and has a distinct epidemiologic setting.

Some cases have been associated with medicines, including penicillamine and certain other drugs. Sun exposure may aggravate disease for some people, but neither sunlight nor a medication explains every case. A clinician will review the timeline, dose changes, and other possible causes before recommending any medication change.

Signs and symptoms

The first changes often arise gradually and may come and go. PF commonly affects the scalp, face, upper chest, and back, but lesions can spread to other skin areas. The exact pattern varies. Some people have a few localized patches; others develop more widespread inflammation.

Fragile superficial blisters: These may be tiny, soft, or already broken by the time they are seen.
Shallow erosions: Open, tender, or weeping patches can form where a blister roof has lifted away.
Scale and crust: Thin scale or yellow-brown crust may collect on an inflamed red or darker-looking base.
Burning or soreness: Some people describe stinging, sensitivity, or localized pain. Itch can occur, but intense itch is not required for PF.
Color change after healing: A darker or lighter mark may remain temporarily after inflammation settles. This is not necessarily a permanent scar.

Skin color and lighting change how redness appears. On darker skin, active inflammation may look violaceous, gray-brown, or darker than the surrounding area rather than bright red. Photos can help a clinician follow change over time, but they cannot establish the diagnosis and should not delay an examination.

PF frequently appears on the scalp, face, and upper trunk. The illustration is a general orientation, not a diagnostic map or a prediction of where an individual will develop lesions.

How PF differs from pemphigus vulgaris

Both disorders belong to the pemphigus family, but they differ in typical target proteins and the depth of the skin split. PF most often involves antibodies to desmoglein 1 and tends to produce superficial skin erosions. Pemphigus vulgaris (PV) more often involves desmoglein 3, sometimes alongside desmoglein 1, and can cause painful mouth sores as well as skin blisters. PF usually spares mucosal surfaces.

This distinction matters because mouth, eye, genital, or throat symptoms should prompt assessment rather than being assumed to be part of uncomplicated PF. A person can have more than one skin or immune condition, and a clinician may consider PV, bullous pemphigoid, impetigo, subacute cutaneous lupus, seborrheic dermatitis, or other blistering and crusting disorders.

How doctors diagnose it

Diagnosis usually requires a dermatologist because several common skin conditions can resemble PF. The clinician asks when the rash began, whether it is painful or itchy, what areas are affected, whether there are mouth or eye symptoms, and what prescriptions or supplements have changed. Examination may include a gentle skin-fragility assessment, but no single physical sign proves PF.

Skin biopsy for routine microscopy: A small sample from a fresh lesion is examined to look for a superficial intraepidermal split and acantholytic cells. Older, crusted, or treated lesions may be less informative, so the site and timing matter.

Skin biopsy for direct immunofluorescence: A second sample is usually taken from nearby normal-looking skin rather than the eroded center. A laboratory looks for intercellular IgG, often with complement, along keratinocyte surfaces. This pattern supports pemphigus and helps distinguish it from other autoimmune blistering diseases.

Blood antibody testing: Indirect immunofluorescence and enzyme-linked immunosorbent assay (ELISA) can detect circulating antibodies, including anti-desmoglein 1. These results help support classification and may be followed over time, but they are interpreted alongside the examination and biopsy rather than in isolation.

Before the appointment, it can help to bring a dated list of new medicines and dose changes, photographs of early lesions, and notes on any mouth, eye, or genital symptoms. Do not stop a suspected medicine or apply leftover steroid or antibiotic treatment solely to test whether the rash improves; either can complicate the clinical picture and medication decisions.

Two biopsy samples may be requested: one from an active lesion for routine histology and a separate perilesional sample for direct immunofluorescence (DIF). Blood tests may add useful antibody information.

Treatment options

The goals are to stop new blisters, let damaged skin heal, prevent infection, reduce discomfort, and limit treatment harms. A dermatologist chooses treatment according to the extent and pace of disease, pain, other health conditions, infection risk, previous response, pregnancy considerations, and local drug approvals. The plan may change as the skin improves or flares.

Limited disease

When PF is localized, a clinician may use topical corticosteroids or other local care. The right strength, site, and duration matter: potent corticosteroids can thin skin or cause other side effects, especially on the face or skin folds. Avoid using prescription creams left over from another condition unless the clinician advises it.

More extensive or persistent disease

More widespread PF may require systemic treatment that controls immune activity. Depending on the person and local guidance, specialists may consider oral corticosteroids, a steroid-sparing medicine such as azathioprine or mycophenolate, dapsone in selected PF cases, or B-cell-directed treatment such as rituximab. Some options are used off-label for PF in certain countries. These medicines need clinician supervision and may require screening, laboratory monitoring, infection precautions, and a gradual taper rather than abrupt stopping.

Evidence and approvals are not identical for every pemphigus subtype. For example, a medicine may have a regulatory indication for PV in one country but not PF. Ask what treatment goal is being targeted, how quickly improvement is expected, which warning signs require a call, what tests are needed, and how the plan will be adjusted if new lesions continue.

Antibiotics are not a treatment for the autoimmune cause. They may be prescribed if a clinician finds a secondary bacterial infection. Using topical or oral antibiotics without a diagnosis can irritate skin, cause side effects, and delay appropriate immune treatment.

There is no single regimen for every person. Disease extent, response, medical history, treatment risks, and access determine the plan.

Skin care while lesions heal

Skin care can support comfort and reduce avoidable trauma, but it does not treat the antibody process itself. Ask the dermatology team for wound-care instructions that fit the affected body site and treatment plan. General principles may include:

Wash gently with lukewarm water and a mild, fragrance-free cleanser; avoid scrubbing, exfoliating acids, retinoids, and fragranced products on open skin.
Pat dry rather than rubbing. If advised, use a bland ointment and a nonstick dressing over areas that rub against clothing.
Choose loose, soft clothing and reduce friction from straps, hats, or rough seams where practical.
Do not pick crusts or intentionally open blisters. Contact the care team for guidance on dressings or large painful areas.
Ask whether sun protection is useful for your pattern, especially if facial or sun-exposed areas worsen. Use shade, protective clothing, and a sunscreen tolerated by your skin on intact areas.
Keep follow-up appointments and report new areas, persistent pain, drainage, fever, or medication side effects.

If systemic immune-suppressing treatment is used, ask the prescribing clinician about vaccination timing, infection precautions, and which symptoms should prompt same-day advice. Do not start supplements or stop routine vaccines without discussing them when medicines alter immune function.

Low-friction habits may make fragile areas more comfortable. Wound-care products and dressing choices should be matched to the lesion and reviewed with the clinician.

When to seek medical care

Arrange a dermatology appointment for blisters that recur, unexplained shallow sores, or crusted areas that are not healing. Assessment is particularly important when lesions are spreading, involve the face or scalp, or begin after a medication change. Bring a medication list and tell the clinician about any prior autoimmune disease or treatment.

Contact a clinician promptly for fever, increasing warmth or swelling, worsening pain, pus, rapidly expanding redness, or feeling unwell. Those symptoms may indicate infection or another complication. Seek urgent care if extensive skin loss makes it hard to drink, urinate normally, or maintain fluid intake, or if you develop severe weakness.

New mouth, eye, genital, or throat sores need prompt review because they are not typical of ordinary PF and may indicate another diagnosis. Eye pain, vision changes, trouble swallowing, or breathing difficulty require urgent assessment.

Use local urgent or emergency services for severe symptoms. The diagram is general information and does not replace a clinician’s triage advice.

Conditions that can look similar

PF is not the only cause of crusted or eroded skin. Impetigo can form superficial sores and honey-colored crust, particularly in children, and may spread by direct contact. Seborrheic dermatitis commonly affects the scalp and face with greasy scale, while eczema or contact dermatitis may be itchier and follow a particular exposure pattern. Subacute cutaneous lupus can create scaly, sun-sensitive patches. Other pemphigus disorders and autoimmune blistering diseases also need different tests and treatment plans.

These conditions can overlap in appearance, and a person may have more than one issue at once. For example, an open erosion can become infected, or an irritated scalp may coexist with PF. That is why a clinician may swab a suspicious area, review the distribution, select a fresh lesion for biopsy, and interpret tissue and blood results together. Avoid using a photograph, an online symptom checker, or a trial of someone else’s prescription medicine as a substitute for this evaluation.

If an initial biopsy is inconclusive but the rash continues to evolve, ask the dermatologist what the next step should be. The best biopsy site can change over time, and prior treatment or a healing lesion may affect how clearly a sample shows the process. A planned follow-up can be more useful than repeatedly changing skin-care products on your own.

Questions to bring to a follow-up visit

Because PF and its treatments can have a long course, clear follow-up makes care easier to manage. Consider asking what signs count as disease activity, how quickly the team expects new lesions to stop, what skin-care routine is safe on open areas, and whom to contact after hours. If treatment includes systemic medicine, ask which blood tests or infection screens are needed, how vaccines fit with the plan, and what side effects require same-day advice.

Tell the clinician about all medicines, over-the-counter products, supplements, past infections, and upcoming procedures. If a medication might be contributing, the prescriber can weigh the evidence and plan any change safely. Keep a brief photo diary in consistent lighting if the clinician finds it helpful, but avoid photographing intimate areas or sharing images outside the secure care channel.

Living with recurring erosions can affect sleep, clothing choices, work, and confidence. Let the care team know if pain, appearance, or treatment demands are interfering with daily life. Practical adjustments and emotional support are part of care, alongside controlling the immune process.

Outlook and follow-up

The course varies. Some people achieve remission and eventually stop treatment under medical guidance; others have a longer course with periods of improvement and relapse. Early recognition can help limit ongoing skin injury and make treatment safer. Improvement may take time, and residual color change can outlast active inflammation.

Follow-up helps the team judge whether new blisters have stopped, whether existing erosions are healing, and whether medicines are causing side effects. In some cases, antibody levels provide additional context, but the appearance and symptoms of the skin remain important. Keep a simple record of new lesions, treatment changes, infections, and questions that arise between visits.

Frequently asked questions

Is pemphigus foliaceus contagious?

No. It is an autoimmune disease and does not spread from person to person. The skin can develop a secondary infection after blisters break, but that infection risk is separate from the cause of pemphigus.

Does pemphigus foliaceus affect the mouth?

Usually it does not. Pemphigus foliaceus typically affects skin because its target, desmoglein 1, is partly compensated for in many mucosal areas by desmoglein 3. Mouth or eye sores should be assessed because they may point to another condition or pemphigus subtype.

What do the blisters look like?

The blisters are very superficial and fragile, so they often rupture before they are noticed. A clinician may see shallow raw areas, scale, crust, or red patches instead of intact blisters, commonly on the face, scalp, chest, or back.

How is pemphigus foliaceus diagnosed?

Diagnosis generally combines the clinical pattern with a skin biopsy for routine microscopy, a separate sample from nearby normal-looking skin for direct immunofluorescence, and blood tests for pemphigus antibodies such as anti-desmoglein 1. No single photo or home test can confirm it.

Can sunlight trigger a flare?

Sun exposure may worsen pemphigus foliaceus in some people, but it is not a universal trigger. Ask the dermatologist whether sun protection is appropriate for your pattern and treatment, and avoid deliberate tanning or intense exposure while the disease is active.

Will I need oral medication?

Not always. Limited disease may be treated with clinician-directed topical therapy. More widespread or persistent disease may need systemic treatment to control inflammation and limit skin damage. The choice depends on extent, health history, infection risk, and local treatment approvals.

Should I stop a medicine that might be related?

Do not stop a prescription on your own. Some medications have been linked to drug-induced pemphigus, but timing and other causes matter. Share a complete medication and supplement list with your prescriber so they can decide whether a safe substitute or supervised change is needed.

References and further reading

Medical information notice: This article is for general education and does not replace diagnosis or individualized treatment. A qualified clinician should assess new, spreading, painful, or infected blisters and advise on prescription medicines. Seek urgent care for breathing difficulty, eye or vision symptoms, severe illness, or extensive skin loss.

Trending